Secondary Cytoreductive Surgery Requires Careful Selection in Recurrent Ovarian Cancer
Amer Karam, MD, discusses the role of secondary cytoreductive surgery in ovarian cancer and the need for careful patient selection, plus the results from 3 clinical trials and the key differences between these efforts.
Role of PARP Inhibition Shifts in Ovarian Cancer as Research Efforts Expand
February 11th 2020Robert L. Coleman, MD, FACOG, FACS, discusses the role of rucaparib as a treatment option for patients with ovarian cancer, how this agent compares with other PARP inhibitors in this space, and where research is headed for these agents.